Research programme: beta catenin inhibitors - Clinical Data

Drug Profile

Research programme: beta catenin inhibitors - Clinical Data

Alternative Names: 316; ATL 316; AV-65; AVB-08; AVB-63; AVB-92; AVN316; LC 363; LC-363 compounds

Latest Information Update: 27 Apr 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avalon Pharmaceuticals
  • Developer Clinical Data
  • Class Small molecules
  • Mechanism of Action Beta catenin inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 01 Apr 2012 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
  • 08 Dec 2009 Pharmacodynamics data from preclinical trials in Cancer presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top